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httpAtherectomy offers no beneﬁts over balloon
angioplasty in tibial interventions for critical
limb ischemia
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Candice R. Chipman, MD, and Jean M. Panneton, MD, Norfolk, Va
Background: Endovascular adjuncts, like atherectomy, were developed to improve outcomes of endovascular arterial
interventions. The true impact of atherectomy on endovascular outcomes remains to be determined, and little data exist
on the inﬂuence of atherectomy on tibial interventions. Our study compares early and late outcomes of tibial intervention
with angioplasty vs atherectomy-assisted interventions.
Methods:We completed a retrospective review of all tibial interventions between 2008 and 2010. Outcomes were analyzed
using single and multivariate analysis, Cox regression, and Kaplan-Meier curves. Primary outcomes were primary, primary
assisted, and secondary patency rates, as well as limb salvage and survival rates.
Results:Over a 2-year period, 480 tibial interventions were completed for 421 patients. Eighty-seven percent (n[ 418) of
interventions were performed for critical limb ischemia (CLI) and 13% (n[ 62) for claudication. The CLI cohort of 418
interventions was analyzed. These patients had a mean age of 71 years with a mean follow-up time of 16 6 15 months
(range, 0-59 months). Of the 418 interventions, 339 underwent percutaneous transluminal angioplasty (PTA): 333 PTA
alone, six PTA D stent. The remaining 79 interventions received atherectomy: 33 laser, 13 directional, and 33 orbital
either alone or in conjunction with PTA (11 atherectomy only, 68 atherectomy D PTA). The groups did not differ
signiﬁcantly in terms of demographics, risk factors, or technical success. The atherectomy group had more TASC B lesions
(54% vs 38%; P[ .013), while the PTA-alone group had more TASC D lesions (25% vs 13%; P[ .004). TASC A and C
lesions did not differ signiﬁcantly between the groups. No signiﬁcant differences existed with respect to the early (30-day)
outcomes of loss of patency (11% vs 13%; P[ .699), complications (8% vs 13%; P[ .292), or major amputation (17% vs
13%; P[ .344) in the PTA-alone group vs the atherectomy-assisted group. Kaplan-Meier analysis revealed no difference
for all primary outcomes of PTA alone vs the atherectomy-assisted group at 12 and 36 months: primary patency (69%,
55% vs 61%, 46%; P[ .158), primary assisted patency (83%, 71% vs 85%, 67%; P[ .801), secondary patency (94%, 89%
vs 95%, 89%; P[ .892), limb salvage (79%, 70% vs 81%, 77%; P[ .485), or survival (77%, 56% vs 80%, 50%; P[ .944).
Conclusions: The adjunctive use of atherectomy offered no improvement in primary outcomes over PTA alone in either
early or late outcomes in CLI patients who underwent endovascular tibial interventions. Considering the additional cost
and increased procedural time, these ﬁndings put into question the routine use of adjunctive atherectomy. (J Vasc Surg
2013;58:941-8.)Studies of percutaneous infrainguinal interventions
have demonstrated the efﬁcacy of endovascular interven-
tions, reporting both a limb salvage rate and secondary
patency rate of nearly 80%.1 Given the increased utilization
of endovascular interventions, numerous studies have
focused on the various tools for arterial treatment, such
as percutaneous transluminal angioplasty (PTA) with or
without (6) stent and atherectomy 6 PTA 6 stent.2,3
Interestingly enough, the literature on adjuncts like athe-
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://dx.doi.org/10.1016/j.jvs.2013.04.024femoral artery and the popliteal artery.4-7 In practice, the
endovascular treatment options used in the suprapopliteal
arteries have been extended further distally into the tibial
runoff vessels with little data on the effectiveness and
factors that inﬂuence these tibial interventions.
A 2009 review of the state of tibial interventions for
critical limb ischemia (CLI) summarized the deﬁciencies
of the current literature by pointing out a lack of data to
determine “the most appropriate and beneﬁcial role of
endovascular intervention,” as well as a marked need for
comparative data pertaining to treatment methods.8
Furthermore, the impact of patient factors (eg, comorbid-
ities) on each treatment is yet to be elucidated and signiﬁ-
cantly affects both technical and patient-oriented
outcomes.9 Given the signiﬁcantly increased cost and
procedural time associated with the use of newer atherec-
tomy techniques as compared with PTA,10 data directly
comparing the efﬁcacy and outcomes of PTA vs
atherectomy-assisted intervention when used to treat tibial
occlusive disease is necessary in order to best determine the
place for each technique in infrapopliteal interventions.
Thus, this study sought to ﬁll the void by comparing941
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atherectomy-assisted intervention in the tibial territory.
The goal of our study was to determine if the adjunctive
use of an atherectomy device during endovascular tibial
intervention impacted primary outcomes in patients with
CLI.
METHODS
We conducted a retrospective review of all patients
who underwent endovascular tibial interventions for
peripheral arterial disease (PAD) between 2008 and
2010. Data collected from the medical record included
patient demographics, comorbidities, prior arterial inter-
ventions, procedural and anatomic details, and outcomes.
Procedure time was collected from our procedural elec-
tronic medical record entered by our endovascular staff
and is deﬁned as the time from injection of local anesthetic
to when the interventional sheath is either secured or
removed. The procedures reviewed in this study were per-
formed over an 0.014-in or 0.018-in platform. PTA was
performed in either transluminal or, rarely, a subintimal
fashion. The atherectomy devices used included Excimer
laser atherectomy (Spectranetics Corp, Colorado Springs,
Colo), Diamondback 360 orbital atherectomy (Cardio-
vascular Systems Inc, St. Paul, Minn), and SilverHawk
directional atherectomy (ev3 Endovascular Inc, Plymouth,
Minn). Isolated PTA vs atherectomy (as well as which athe-
rectomy device used) were determined by surgeon prefer-
ence. As our institution affords us a very large number of
surgeons, some individuals routinely use a speciﬁc atherec-
tomy device in a majority of their peripheral interventions,
while others use PTA adjuncts very sparingly. On a case-by-
case basis, the basic charge for the addition of the various
atherectomy devices ranges from $3000 to $5000 at our
institution. Selective stenting was utilized for any lesion
with a residual stenosis >30% after intervention. TASC
classiﬁcations were determined according to the TransAt-
lantic Inter-Society Consensus for the Management of
Peripheral Arterial Disease (TASC-II) guidelines.11,12
Primary outcomes for this study were patency (primary,
primary assisted, and secondary), reintervention rate, limb
salvage rate, and survival. Patency was determined by the
results of duplex ultrasound, ankle brachial indices, and/
or angiograms during postprocedural follow-up visits or
reintervention procedures. Primary patency was deﬁned
as uninterrupted patency postprocedure unaided by
follow-up procedure. Primary assisted patency was deﬁned
as patency that was never lost, but rather prophylactically
protected by reintervention. Finally, secondary patency
was deﬁned as patency restored after occlusion via a repeat
procedure. Follow-up surveillance protocols included
routinely performed 1-, 3-, 6-, and 12-month ultrasound
surveillance of our endovascular interventions. A drop in
ankle brachial index or arterial duplex evidence of >75%
stenosis warranted repeat angiogram. If angiogram veriﬁed
restenosis, a reintervention was attempted. Secondary
outcomes for this study were 30-day complications, symp-
tomatic relief at ﬁrst follow-up, and Rutherford scoreimprovement. Complications were divided into local/
vascular (hematoma, pseudoaneurysm, bleeding at access
site, compartment syndrome, and wound infection) vs
systemic/remote (30-day mortality, development of
congestive heart failure/myocardial infarction/arrhythmia,
thrombosis, atheroembolism, stroke/transient ischemic
attack, deep vein thrombosis/pulmonary embolus, and
development of renal insufﬁciency). Determination of
complications (eg, atheroembolism) was made via careful
review of the completion angiogram and corroborated by
an improvement in duplex ultrasound postprocedure.
Both early (30-day) and late outcomes were analyzed.
Data were collected in Microsoft Excel (Microsoft Corp,
Redmond, Wash), and statistical analysis was performed
using SPSS software (IBM Corp, Armonk, NY). Discrete
variables were analyzed using the two-tailed heteroscedas-
tic Student t-test and multivariate analysis. Limb salvage,
patency, and mortality were evaluated using Kaplan-
Meier life tables and compared using log-rank tests.
Hazard ratios were determined using Cox regression anal-
ysis. The cutoff for statistical signiﬁcance was deﬁned as
P < .05. P values <.05 on univariate analysis were included
in the multivariate analysis. The study design and methods
were approved by the Eastern Virginia Medical School
Institutional Review Board.
RESULTS
A total of 480 tibial interventions were performed in
421 patients. Patients who presented with claudication
(Rutherford class 1-3) were excluded, and only the CLI
cohort of 418 interventions was selected for analysis. Pre-
procedural characteristics for the CLI cohort included
age (mean, 71 years; range, 39-95 years), with 64% men,
and a mean body mass index of 27. The remaining risk
factors included a history of smoking (64%); diabetes,
deﬁned as a hemoglobin A1C $ 6.5 (72%); hypertension,
deﬁned as a systolic pressure >140 mm Hg or a diastolic
pressure >90 mm Hg (92%); hyperlipidemia/hypercholes-
terolemia, deﬁned as total cholesterol >200 mg/dL or
triglycerides >200 mg/dL (65%); chronic obstructive
pulmonary disease (15%); coronary artery disease/myocar-
dial infarction (54%), cerebrovascular accident/transient
ischemic attack (27%); renal insufﬁciency, deﬁned as creat-
inine >1.5 if male and >1.2 if female, or end-stage renal
disease (39%); prior lower extremity bypass (13%); prior
ipsilateral lower extremity endovascular procedure (26%);
prior ipsilateral tibial endovascular procedure (4%); and
bilateral peripheral arterial disease (77%). All patients had
CLI: Rutherford class 4 (ie, rest pain [33%]) and Ruther-
ford class 5-6 (ie, tissue loss [67%]).
All patients underwent endovascular tibial interven-
tions. Of the 418 interventions, 339 underwent PTA
without atherectomy. Three hundred thirty-three limbs
were treated with PTA alone, while six PTA procedures
were accompanied by stenting (to treat minor dissection
in four and to treat residual stenosis >30% in two). The
remaining 79 interventions were performed with atherec-
tomy: 33 laser, 13 directional, and 33 orbital. Of the 79
Table. Preprocedural characteristics for PTA versus
atherectomy
Variable PTA Atherectomy P
Mean age, years 71 70 .823
Male gender 60 70 .077
Tobacco use 65 62 .692
Diabetes 71 76 .313
Hypertension 91 97 .005
Hyperlipidemia 64 67 .743
Chronic obstructive pulmonary
disease
15 15 .955
Coronary artery disease/myocardial
infarction
53 60 .225
Cerebrovascular accident/transient
ischemic attack
25 33 .172
Renal insufﬁciency 38 41 .788
Rutherford class 4 33 30 .611
Rutherford class 5-6 67 70 .598
TASC A 4 4 .971
TASC B 38 54 .012
TASC C 11 10 .692
TASC D 25 13 .049
Isolated tibial disease 21 20 .761
PTA, Percutaneous transluminal angioplasty.
Values represent % of population.
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while 68 utilized atherectomy in conjunction with PTA.
No atherectomy interventions underwent stenting. Two
hundred forty of the 418 procedures treated multisegment
disease (ie, both supra- and infrapopliteal lesions), while the
remaining 178 procedures treated tibial disease only. The
average follow-up time for the entire CLI cohort was 16
months (range, 0-59 months). Comparative demographic,
risk factor, and lesion characteristic data between patient
populations who underwent PTA alone vs atherectomy-
assisted interventions are reported in the Table.
The groups did not differ signiﬁcantly in terms of age,
gender, or risk factors. The atherectomy group did have
a signiﬁcantly higher proportion of hypertension, but this
was found to be a statistically insigniﬁcant factor in the
determination of primary and secondary patient outcomes.
The atherectomy group had signiﬁcantly more TASC B
lesions (54% vs 38%; P ¼ .012), while the PTA-alone group
had signiﬁcantly more TASC D lesions (25% vs 13%; P ¼
.004). TASC A and C lesions did not differ signiﬁcantly
between the two groups. Finally, PTA-alone and
atherectomy-assisted groups did not differ in whether the
treated lesion was occlusive or stenotic; both groups had
44% occlusion.
The technical success rate for all procedures was 97%.
Technical success of the procedure was deﬁned as treat-
ment of the target lesion and <30% residual stenosis.
Mean operative times showed a trend toward a difference
when comparing the PTA-alone cohort (97 minutes)
with the entire atherectomy cohort (atherectomy 6 PTA,
103 minutes; P ¼ .059). The adjunctive use of atherec-
tomy with PTA, however, signiﬁcantly increased mean
operative time by 8% compared with PTA alone (97 vs
105 minutes; P ¼ .029). There was no signiﬁcantdifference in technical success rate based on treatment
type (97% PTA vs 98% atherectomy; P ¼ .710). No signif-
icant differences existed for PTA vs atherectomy with
respect to the early (30-day) outcomes of loss of patency
(11% vs 13%; P ¼ .699), complications (8% vs 13%; P ¼
.292), or major amputation (17% vs 13%; P ¼ .344).
Furthermore, there was no difference between treatment
groups in symptomatic relief at ﬁrst follow-up (61% vs
65%; P ¼ .529) or Rutherford score improvement (70%
vs 69%; P ¼ .810).
Long-term outcomes are presented in Figs 1-4.
Notably, Kaplan-Meier and Cox regression analysis
revealed no difference in the PTA-alone vs atherectomy-
assisted group at the 6-, 12-, 24-, and 36-month time
points for all primary outcomes: primary patency (80%,
69%, 62%, 55% vs 71%, 61%, 51%, 46%; P ¼ .168), primary
assisted patency (91%, 83%, 78%, 71% vs 89%, 85%, 74%,
67%; P ¼ .801), and secondary patency (97%, 94%, 92%,
90% vs 95%, 95%, 95%, 89%; P ¼ .892), as well as limb
salvage (85%, 79%, 73%, 70% vs 84%, 81%, 77%, 77%;
P ¼ .485) and survival (83%, 75%, 65%, 55% vs 87%,
74%, 66%, 52%; P ¼ .944). Standard error values remained
under 10% at all time points (Figs 1-4). For the entire
cohort, seven patients had limb loss without ever losing
secondary patency. One of these patients underwent an
amputation without loss of primary patency. Additionally,
there were no signiﬁcant long-term differences in either
local (10% vs 14%; P ¼ .417) or systemic (3% vs 5%; P ¼
.506) complication rates between treatment groups of
PTA vs atherectomy. For the PTA vs the atherectomy
groups, neither reintervention rates (25% vs 37%; P ¼
.054), nor average number of reinterventions required
per patient per year (1.06 vs 0.64 per patient per year;
P ¼ .456) differed between treatment groups. Notably,
the overall rate of thromboembolic complications was 6%
(one patient with distal embolization and 26 patients
with thrombosis). The rate of thromboembolic complica-
tions with the PTA-alone group (6.2%) vs the atherectomy
adjunctive group (7.5%) was not statistically different, and
our study was not powered to analyze this endpoint.
Single and multivariate analysis of the effect of patient
comorbidities and anatomic factors on patient outcomes
was performed. For the entire cohort, renal insufﬁciency
worsened primary outcomes of primary patency (hazard
ratio [HR], 1.5 for loss; P ¼ .045), limb salvage (HR, 2.2
for loss; P < .001), and survival (HR, 3.1 for mortality;
P < .001). Furthermore, primary patency was improved
by 2þ vessel postoperative runoff (HR, 0.6 for patency
loss; P ¼ .016) and that survival was worsened by tissue
loss (ie, Rutherford score >4; HR, 1.6 for mortality;
P ¼ .015).
For the PTA-alone group, renal insufﬁciency worsened
primary (HR, 1.6; P ¼ .005), primary assisted (HR, 1.9;
P ¼ .002), and secondary (HR, 2.2; P < .001) patency
as well as limb salvage (HR, 2.2; P ¼ .001). Furthermore,
treatment of a TASC B lesion signiﬁcantly improved
primary patency for the PTA-alone group (HR, 0.7;
P ¼ .027).
Fig 1. Primary patency outcomes and Kaplan-Meier life tables for patients with critical limb ischemia (CLI) who
underwent either atherectomy (blue) or percutaneous transluminal angioplasty (PTA) (red). Cox regression analysis
revealed no signiﬁcant difference in primary patency based on treatment method. Results shown at the 6-, 12-, 24-, and
36-month time points. m, Months.
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lesion signiﬁcantly worsened secondary patency (HR, 5.2;
P ¼ .035). No other patient or anatomic factors were
found to signiﬁcantly impact outcomes for the atherectomy
treatment group.
DISCUSSION
Infrapopliteal PTA has been demonstrated to be effec-
tive in treating CLI with high limb salvage rates (84%-89%)
but lower primary patency rates (31%-51%).13,14 The desire
for improved patency rates and thus patient outcomes has
driven the use of atherectomy as an alternative or adjunc-
tive technique to treat PAD. Previous studies have shown
that interventions using atherectomy are effective. Primary
and secondary patency rates of 67% and 91%, respectively,
after 1 year and 60% and 80% after 2 years have been re-
ported in a 2007 study of 36 patients, all tibial interven-
tions, who were treated with directional atherectomy.15
The Deﬁnitive LE (Determination of Effectiveness of
SilverHawk/TurboHawk Peripheral Plaque Excision
Systems for the Treatment of Infrainguinal Vessels/LowerExtremities) trial of 800 patients (96 tibial CLI cases)
treated with stand-alone directional atherectomy recently
reported a 12-month freedom from amputation of 95%
and primary patency rate of 71% for their CLI cohort
(n ¼ 201).16 A study of 201 lesions (94% infrapopliteal)
treated with rotational atherectomy reported an improve-
ment of Rutherford scale of 78% of patients at the
6-month time point.17 Finally, we recently published our
institutional experience with 245 patients treated with laser
atherectomy and reported 1- and 3-year primary patency
rates of 48% and 37%, secondary patency rates of 69%
and 51%, and limb salvage rates of 91% and 83%, respec-
tively.18 While each individual method of atherectomy
was deemed successful, there is a notable lack of uniformity
in reporting standards for success, as exempliﬁed by the
OASIS (Orbital Atherectomy System for the Treatment
of Peripheral Vascular Stenosis) trial reporting only very
short-term (6-month) results.17 Furthermore, there is an
overall paucity of studies focusing solely on endovascular
tibial interventions. As it stands, the efﬁcacy and outcomes
of such interventions remain largely unexamined. Such an
Fig 2. Primary assisted patency outcomes and Kaplan-Meier life tables for patients with critical limb ischemia (CLI)
who underwent either atherectomy (blue) or percutaneous transluminal angioplasty (PTA) (red). Cox regression
analysis revealed no signiﬁcant difference in primary assisted patency based on treatment method. Results shown at the
6-, 12-, 24-, and 36-month time points. m, Months.
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potentially effective, its use is associated with increased
cost and procedural time.10 Our study also conﬁrmed
this prolonged procedural time required for adjunctive
atherectomy. Thus, the optimal place of atherectomy in
an endovascular surgery practice must be determined while
taking into account its beneﬁts and drawbacks.
Perhaps the most important factor that has hindered
the determination of the true efﬁcacy as well as the best
role of each endovascular technique in practice is the lack
of long-term studies directly comparing techniques in
a randomized controlled trial, especially in the infrapopli-
teal segment. A 2-year follow-up study comparing femoral/
popliteal PTA vs atherectomy suggested that atherectomy
improved neither clinical nor hemodynamic outcomes,
and it actually demonstrated worsened outcomes with the
use of directional atherectomy to treat lesions >2 cm.19
Other studies in the femoral/popliteal segment suggest
that atherectomy may have a place treating longer
lesions16,20 or as an adjunct to treating advanced lesions
(TASC C or D) when PTA alone has failed.21 While theseresults are for femoral/popliteal disease, they call into ques-
tion the indications for atherectomy use in the treatment of
PAD.
The endovascular treatment picture is even less clear
as it pertains to tibial interventions. Studies focusing on
infrapopliteal treatments are scarce and have obvious
drawbacks precluding the development of generali-
zable conclusions for the role of stand-alone PTA vs
atherectomy-assisted PTA. A 2011 study examined the
6-month outcomes of 49 tibial interventions comparing
PTA vs directional atherectomy. This study concluded
that the techniques had comparable outcomes, and either
could be used to effectively treat tibial disease.22 A 2012
study analyzed the outcomes of 50 patients who under-
went either orbital atherectomy as an adjunct to PTA
or PTA alone to treat calciﬁc infrapopliteal lesions. This
study concluded that orbital atherectomy as an adjunctive
treatment to PTA improved the freedom from target vessel
revascularization as well as all-cause mortality, up to
1 year.23 However, the conclusions of both studies are
weakened by small sample sizes, relatively short-term
Fig 3. Secondary patency outcomes and Kaplan-Meier life tables for patients with critical limb ischemia (CLI) who
underwent either atherectomy (blue) or percutaneous transluminal angioplasty (PTA) (red). Cox regression analysis
revealed no signiﬁcant difference in secondary patency based on treatment method. Results shown at the 6-, 12-, 24-,
and 36-month time points. m, Months.
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long-term outcomes of PTA and atherectomy remain
largely unexamined in the tibial vessels and require a greater
patient population to be powered to make signiﬁcant
recommendations.
This study evaluated the outcomes of 418 limbs and
was powered to analyze outcomes up to 3 years postproce-
dure. The results suggest that there is no statistically signif-
icant difference in either primary or secondary outcomes
for patients who underwent PTA alone vs atherectomy 6
PTA. Furthermore, neither short- nor long-term outcomes
were different. Thus, our study demonstrated no measur-
able outcomes-based advantage to either technique.
Although the outcomes are similar, PTA and atherectomy
are not necessarily interchangeable techniques for the treat-
ment of tibial disease. The increased cost of atherectomy
must be considered and may be a deterrent in its use as
a stand-alone treatment, given the similar outcomes.
Furthermore, the increased procedural time and cost asso-
ciated with adjunctive use of atherectomy with PTA call
into question its use as an endovascular adjunct, as thereis no beneﬁt in patient outcomes, and atherectomy may
be associated with an increased risk of distal emboliza-
tion.24 While atherectomy has been heralded as an effective
debulking technique in calciﬁed or advanced (TASC C or
D) lesions,23,25 the results of our study suggest that its
use has no impact on outcomes. Additionally, in this study,
PTA alone was used to treat signiﬁcantly more TASC D
lesions and yet still demonstrated equivalent outcomes to
lesser TASC lesions treated with atherectomy. Further
studies would be required to conﬁrm our result, but this
study suggests that the use of atherectomy in advanced
lesions may be superﬂuous. While atherectomy may be
indicated in heavily calciﬁed or PTA-resistant lesions, its
generalized use as an adjunct to PTA to treat all lesions
does not provide an overall beneﬁt.
One area of concern regarding the results of this study
is the presence of concomitant femoropopliteal lesions and
interventions on these lesions, which had the potential to
be confounding variables. It was possible that outcomes
in patients with multilevel disease/treatments could be
attributed to proximal interventions rather than the index
Fig 4. Limb salvage outcomes and Kaplan-Meier life tables for patients with critical limb ischemia (CLI) who
underwent either atherectomy (blue) or percutaneous transluminal angioplasty (PTA) (red). Cox regression analysis
revealed no signiﬁcant difference in limb salvage based on treatment method. Results shown at the 6-, 12-, 24-, and 36-
month time points. m, Months.
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distribution of proximal lesions in our treatment groups.
There was no signiﬁcant difference between the two groups
in terms of the presence of multisegment disease vs isolated
tibial disease (Table). We then compared the outcomes for
patients with multisegment disease with those with tibial
disease only. We also compared the results from patients
who had multiple levels of disease treated with those with
only tibial disease treated. In both cases, no statistically
signiﬁcant difference was found in any primary outcome.
We were therefore comfortable including patients who
had multisegment disease and underwent multilevel inter-
ventions in this study. Furthermore, we recognize the
discrepancy between secondary patency and limb salvage
in our patient population and attribute the higher amputa-
tion rate to the presence of factors beyond isolated tibial
patency, like the degree of tissue loss, development of
sepsis, and functional outcomes of the patient.
Limitations of this study included its retrospective
design and absence of randomization between patient
cohorts. Unfortunately, one of the major limitations of
our retrospective study is the inability to randomizetreatment groups. Yet our study provides the beginnings
of a framework to honestly examine the utility of such
endovascular adjuncts. Although it is not irrefutable
evidence against the use of atherectomy adjuncts in tibial
interventions, we feel the two groups are comparable
enough in the widely accepted lesion classiﬁcations that
the comparison is warranted. Furthermore, while cost anal-
ysis is beyond the scope of this study, we provide the addi-
tional charge range that the use of an atherectomy can add
for any given case. While this is not intended to be a cost
analysis, it provides a rough idea as to the additional
expense an atherectomy device affords and is variable to
hospital and device. Finally, the atherectomy subgroup
analysis of results based on TASC classiﬁcation results
must be approached with some scrutiny, because the
subgroups are likely too small for meaningful separate
statistical analysis (eg, three patients who underwent athe-
rectomy had TASC A lesions).
CONCLUSIONS
The adjunctive use of atherectomy offered no improve-
ment over PTA in either early or late outcomes in CLI
JOURNAL OF VASCULAR SURGERY
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Considering the additional cost and increased procedural
time, these ﬁndings put into question the routine use of
atherectomy in the treatment of tibial disease, either as
a stand-alone or adjunctive technique.
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